FreeOx has developed the first cerebroprotective therapy designed to preserve the brain during acute ischemic stroke. It is the key piece in stroke treatment, as it focuses on microcirculation and sol...
As part of this agreement, the Alta Life Sciences Spain I FCR fund will be co-managed by both firms. Asabys’ founding partners, Clara Campàs and Josep Sanfeliu, will join the Fund’s Investment Co...
This new vehicle will seek to invest in companies in the life sciences sector, with a specific focus on opportunities related to health and wellness, sustainable nutrition, climate, and the environmen...
The round was led by Inveready, through its Inveready Biotech IV fund, with additional participation from CDTI, Clave Capital, through its Clave Innohealth fund, and current investors i&i Biotech Fund...
Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
Phagos has developed a groundbreaking phage therapy process to fight bacterial diseases. Bacterial diseases already rank as the world’s second leading cause of human mortality, one of the main cause...
Additio Capital, imec.istart, Mobile World Capital Barcelona and technological center Eurecat, along with the asset manager Talenta Gestión, have launched Caravela Ventures, FCRE, a venture capital f...
The Catalunya Lidera Fund represents a major step forward in the ICF’s venture capital strategy, reinforcing its investment role in Catalonia both in terms of the volume of resources mobilized and t...
Nanoligent is a biotechnology company developing targeted cancer therapies using proteins organized in nanoparticles and conjugated with cytotoxic drugs
The fund will have a total of €60 million to finance advanced therapy projects in early development stages, aiming to make them viable and facilitate the creation of new companies attractive to priv...
ARTHEx Biotech is a Valencian clinical-stage biotechnology company focused on developing targeted RNA therapeutics for rare genetic neuromuscular disorders. Its lead program, ATX-01, is currently in c...
This financing round will enable Adaptam to continue advancing its programs and initiate the preclinical phase across multiple oncology indications. As part of the round, Salvatore Cappadona, PhD, and...
